Merrimack Pharma (MACK) Misses Q2 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/9/2026
- Wall Street set for weekly gains with earnings, inflation data on tap
- Oil falls as Trump comments on Iran talks ease supply fears
- Apple cuts iPhone 18 Pro orders due to soft demand, Nikkei Asia reports
- UBS flags level in gold prices where dip buyers will likely emerge
- Telecom stocks tumble on SpaceX spectrum acquisition news
- US consumer sentiment near record low as frustration over economy mounts
- 8.0 Mag. Earthquake 14 Km Sw Of Pitaloza Arriba Panama - USGS
- SpaceX to acquire Grain Management's 800 MHz spectrum portfolio
- 7.6 magnitude earthquake felt in Panama -Â USGS
- CoreWeave stock drops on dilution fears and debt concerns
Cowen Downgrades Merrimack Pharmaceuticals (MACK) to Market Perform
August 5, 2016 9:22 AM EDTCowen downgraded Merrimack Pharmaceuticals (NASDAQ: MACK) from Outperform to Market Perform.
For an analyst ratings summary and ratings history on Merrimack Pharmaceuticals click here. For more ratings news on Merrimack Pharmaceuticals click here.
Shares of Merrimack Pharmaceuticals closed at $5.92 yesterday.
... More


